AEON Biopharma Inc Dossier - Source-backed chat

AEON Biopharma Inc

AEONNYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.74

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.30Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $15M

Enterprise Value $46.6M

Shares Outstanding 49.9M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

AEON Biopharma is a clinical-stage biopharmaceutical company uniquely positioned to disrupt the multi-billion dollar therapeutic neurotoxin market by developing ABP-450 as a biosimilar to BOTOX (onabotulinumtoxinA). Following constructive FDA feedback from its January 2026 BPD Type 2a meeting, the company has a clear regulatory pathway to complete the majority of its analytical comparability program in 2026. Furthermore, AEON has significantly de-risked its balance sheet by reducing outstanding debt by over 90% through a Daewoong note exchange and PIPE financing. While the company faces near-term liquidity constraints with cash expected to fund operations into Q3 2026, its highly differentiated therapeutics-only commercial strategy and strong scientific foundation make it an attractive high-upside opportunity for biotech investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$1.00

Mean target$3.53

High · most bullish analyst$8.40

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5015%

The FDA requests additional clinical or analytical data during the Type 2b meeting, delaying the development timeline of ABP-450. AEON struggles to raise capital on favorable terms in 2H 2026, leading to severe dilution or operational halts. The company fails to regain compliance with NYSE American, resulting in delisting to over-the-counter markets.

Base CaseCentral scenario

$6.7060%

AEON completes the majority of its analytical comparability program in 2026 and requests an FDA BPD Type 2b meeting in late 2026. The company secures additional dilutive or non-dilutive financing in Q3 2026 to extend its cash runway. Development of ABP-450 continues steadily, with the cervical dystonia Phase 3 trial protocol finalized and prepared for launch.

Bull CaseUpside scenario

$8.4025%

The FDA accepts the analytical comparability package for ABP-450 without requiring extensive new clinical trials, accelerating the BLA submission timeline. AEON successfully regains compliance with NYSE American listing standards, triggering positive market sentiment and enabling a highly favorable capital raise. The company initiates its Phase 3 trial in cervical dystonia with rapid enrollment, positioning ABP-450 to capture significant market share from BOTOX upon approval.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

100% sequence match of ABP-450 to BOTOX across all five proteins, validated by advanced mass spectrometry.
Constructive FDA feedback from the January 2026 Type 2a meeting confirming the analytical similarity strategy is reasonable.
Balance sheet significantly strengthened with a >90% reduction in outstanding debt via the Daewoong note exchange.
Exclusive therapeutic development and commercialization rights for ABP-450 in major global markets (US, Canada, EU, UK).
Experienced leadership team bolstered by the appointment of Rob Bancroft as CEO and John Bencich as CFO.

Key Investment Risks

Severe near-term liquidity risk, with cash and cash equivalents only sufficient to fund operations into Q3 2026.
Regulatory risks associated with the 351(k) biosimilar pathway and potential FDA requirements for additional clinical data.
Listing compliance risk under NYSE American continued listing standards.
High dependence on a single pipeline candidate (ABP-450) for all future commercial prospects.

Thesis Invalidation Triggers

FDA rejection of the analytical comparability plan during the planned BPD Type 2b meeting.
Inability to secure additional financing before the exhaustion of cash reserves in Q3 2026.
Delisting of Class A common stock from the NYSE American exchange.
Failure of the upcoming Phase 3 trial in cervical dystonia to meet primary efficacy or safety endpoints.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.